Skip to main content
OpenTrials

Clinical trial condition

Lymphoma, Large B-Cell, Diffuse

Explore clinical trials studying Lymphoma, Large B-Cell, Diffuse. Study availability and eligibility vary by location and protocol.

1,249 public trials 217 recruiting studies
Refine in advanced search Browse all conditions

Lymphoma, Large B-Cell, Diffuse trial results

Completed

A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)

NCT03744676

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +13 more
Locations
  • Local Institution - 0057 Los Angeles, California, United States
  • Local Institution - 0060 Denver, Colorado, United States
  • Local Institution - 0089 Miami, Florida, United States
  • Local Institution - 0081 Orlando, Florida, United States
View all 23 locations
View Trial Details
Completed

Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels

NCT04537715

Conditions
Adenoma, Advanced Malignancies, All Malignancies, +32 more
Locations
  • California Cancer Associates for Research and Excellence, Inc. (cCARE) Encinitas, California, United States
  • The Angeles Clinic and Research Institute Los Angeles, California, United States
  • Northwestern University-Robert H. Lurie Comprehensive Cancer Center Chicago, Illinois, United States
  • South Texas Accelerated Research Therapeutics (START) Midwest Grand Rapids, Michigan, United States
View Trial Details
Completed

A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

NCT03992339

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • Anhui Province Cancer Hospital Hefei, Anhui, China
  • Beijing Cancer Hospital Beijing, Beijing Municipality, China
  • Peking University Third Hospital Beijing, Beijing Municipality, China
  • Chongqing Universtity Cancer Hospital Chongqing, Chongqing Municipality, China
View all 18 locations
View Trial Details
Completed

A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

NCT01855750

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • Tucson, Arizona, United States
  • Greenbrae, California, United States
  • La Jolla, California, United States
  • Los Angeles, California, United States
View all 201 locations
View Trial Details
Completed

Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™

NCT03263026

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • Oncology Specialties: Clearview Cancer Institute Huntsville, Alabama, United States
  • University of Arizona Tucson, Arizona, United States
  • Central Arkansas Radiation Therapy Institute Little Rock, Arkansas, United States
  • Desert Hematology Rancho Mirage, California, United States
View all 39 locations
View Trial Details
Completed

Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma

NCT00670358

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • Mayo Clinic in Florida Jacksonville, Florida, United States
  • Mayo Clinic Rochester, Minnesota, United States
View Trial Details

Related conditions